Professor Rachael Morton is the Deputy Director at the CTC and also leads the Health Economics and Health Technology Assessment teams. She specialises in trial-based and modelled economic evaluation, patient reported outcome measures (PROMs) and elicitation of patient preferences using discrete choice experiments. Her research incorporates patient-centred and economic outcomes into clinical trials of diagnostic tests, new treatments and models of care to facilitate policy decision-making on the basis of cost-effectiveness.

 

Research interests

• Health economics of cancer and chronic diseases
• Clinical trials
• Health equity in disadvantaged populations both in Australia and overseas.
• Patient reported outcome measures (PROMs)
• Environmental impacts of healthcare
• Measurement of quality of life and well-being

 

Teaching and supervision

Rachael coordinates short courses in health economics for government and industry and currently supervises five PhD candidates.

 

Expertise

• Within-trial and modelled economic evaluation
• Preference elicitation
• Outcomes assessment
• Health equity
• Chronic Kidney Disease
• Melanoma and other cancers

 

Professional Associations

• Board Director, Australian Clinical Trials Alliance (ACTA) member since 2016; Co-chair ACTA Reference Group – “Research Prioritisation: tools and criteria” since 2017
• Past President, Health Services Research Association of Australia and New Zealand (HSRAANZ), member since 2011
• Co-Convenor, Health Economists Alongside Trials (HEAT) special interest group with ACTA since 2020
• Faculty Member, Melanoma Institute Australia, since 2017
• Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Advisory Committee Member and Convenor, ANZDATA PROMs Working Group, since 2016
• International Health Economics Association (IHEA) Program Chair 2018-2021, member since 2008
• International Society for Pharmacoeconomic and Outcomes Research (ISPOR), member since 2009
• Health Economists Study Group – UK (HESG) member since 2010
• Cochrane Equity Methods Group member since 2013
• Australia and New Zealand Society of Nephrology (ANZSN) member since 1996

 

Publications

View Rachael's publications.